구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chronic Myeloid Leukemia + NK cell (Chronic Myeloid Leukemia + NK cell) Center for International Blood and…·Chronic Myeloid Leukemia 46 trials |
|---|---|
Overview Program | Chronic Myeloid Leukemia + NK cell |
Overview Company | Center for International Blood and Marrow Transplant Research |
Overview Modality | CGT |
Overview Target | Chronic Myeloid Leukemia |
Overview Indication | Chronic Myeloid Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the TAM Receptor |
MoA Biomarker | biomarker-driven resistance persist |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.. T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limi… |
Toxicology CRS | Reported |
Clinical Safety signal | T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.. T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limi… |
Clinical Reported OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00448357 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00448357 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chronic Myeloid Leukemia + NK cell (Chronic Myeloid Leukemia + NK cell) Center for International Blood and…·Chronic Myeloid Leukemia 46 trials |
|---|---|
Overview Program | Chronic Myeloid Leukemia + NK cell |
Overview Company | Center for International Blood and Marrow Transplant Research |
Overview Modality | CGT |
Overview Target | Chronic Myeloid Leukemia |
Overview Indication | Chronic Myeloid Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the TAM Receptor |
MoA Biomarker | biomarker-driven resistance persist |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.. T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limi… |
Toxicology CRS | Reported |
Clinical Safety signal | T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.. T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limi… |
Clinical Reported OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00448357 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00448357 |
추천 비교
추천 비교